Hims & Hers Health Inc. (NYSE:HIMS) shares are trading lower Tuesday after the company reported worse-than-expected third-quarter financial results Monday after the market closed. Also, Needham maintained a Buy rating on the stock and lowered its price target from $42 to $32.
- Hims & Hers Health stock is facing resistance. Why are HIMS shares declining?
Hims & Hers Q3 Misses Estimates, Revenue Rises 49%
Hims & Hers reported a third-quarter loss of 14 cents per share, versus the consensus estimate of earnings of 8 cents. It reported revenue of $890.373 million, up 49% from a year earlier, missing the consensus estimate of $892.888 million. Subscribers grew to nearly 2.8 million, up 13% from a year earlier. Domestic revenue rose 21%, and international revenue rose more than 300%.
“We delivered those results while intentionally pacing marketing spend ahead of several planned expansions to our platform in the fourth quarter, which we expect will set us up well heading into 2027,” said Yemi Okupe, Hims & Hers’ chief financial officer. He said revenue growth accelerated for the second straight quarter.
Andrew Huberman Joins Board; Needham Lowers Target to $32 From $42
Hims & Hers appointed Andrew Huberman, Ph.D., to its board of directors. Needham analyst Ryan MacDonald maintained a Buy rating on the stock and lowered his price target to $32 from $42.
Hims & Hers Tightens 2026 Revenue Outlook; Guides Fourth Quarter
Hims & Hers tightened its full-year 2026 revenue guidance to a range of $3.13 billion to $3.15 billion. For the fourth quarter, it expects revenue of $875 million to $895 million.
Hims & Hers Shares Edge Lower
HIMS Price Action: At the time of publication, Hims & Hers shares are trading 0.86% lower at $22.74, according to data from Benzinga Pro.
Image via Shutterstock
